Brief
Mubadala Bio launches adalimumab and ustekinumab for immune disorders
The UAE manufacturer introduced two biologic drugs for rheumatoid arthritis, psoriasis and Crohn's disease.
By Felo News Desk · Published
Mubadala Bio, the UAE's national pharmaceutical manufacturer, announced the launch of two biologic treatments – adalimumab and ustekinumab – through its BioVenture Healthcare facility on 7 October 2026. Both medicines are prescription‑only and target immune‑mediated diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis and non‑infectious uveitis.
Adalimumab is a monoclonal antibody that blocks tumour necrosis factor, while ustekinumab inhibits interleukins 12 and 23. The rollout aims to broaden access to advanced therapies in the UAE and reinforce the country's role as a pharmaceutical hub.
Dr Esam Mohamed, CEO of Mubadala Bio, said the addition reflects the firm’s effort to broaden specialised treatment options. Deputy CEO Hamad Al Marzouqi added that the expanded portfolio demonstrates progress in localising innovative medicines.
Key facts
- Mubadala Bio launched adalimumab and ustekinumab on 7 Oct 2026 (gulfnews.com)
- Adalimumab targets TNF and treats rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis and non‑infectious uveitis (gulfnews.com)
- Ustekinumab inhibits IL‑12 and IL‑23 and is used for moderate‑to‑severe plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis (gulfnews.com)
- Both drugs are available by prescription only in the UAE (gulfnews.com)
- CEO Dr Esam Mohamed said the launch broadens access to specialised treatment options (gulfnews.com)
- Deputy CEO Hamad Al Marzouqi said the portfolio expansion shows progress in localising innovative treatments (gulfnews.com)
Sources
- [1] gulfnews.com — originally reported as “UAE pharmaceutical manufacturer Mubadala Bio launches two treatments for immune disorders”
